Fintel reports that on August 7, 2023, HC Wainwright & Co. reiterated coverage of Opko Health (NASDAQ:OPK) with a Buy recommendation.
Analyst Price Forecast Suggests 121.26% Upside
As of August 2, 2023, the average one-year price target for Opko Health is 4.40. The forecasts range from a low of 2.02 to a high of $8.92. The average price target represents an increase of 121.26% from its latest reported closing price of 1.99.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Opko Health is 863MM, a decrease of 0.54%. The projected annual non-GAAP EPS is -0.22.
What is the Fund Sentiment?
There are 393 funds or institutions reporting positions in Opko Health. This is a decrease of 26 owner(s) or 6.21% in the last quarter. Average portfolio weight of all funds dedicated to OPK is 0.04%, a decrease of 54.16%. Total shares owned by institutions decreased in the last three months by 4.16% to 187,730K shares. 
The put/call ratio of OPK is 0.26, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,729K shares representing 1.65% ownership of the company. No change in the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 11,078K shares representing 1.43% ownership of the company. In it's prior filing, the firm reported owning 10,950K shares, representing an increase of 1.16%. The firm increased its portfolio allocation in OPK by 13.41% over the last quarter.
IWM - iShares Russell 2000 ETF holds 8,756K shares representing 1.13% ownership of the company. In it's prior filing, the firm reported owning 9,366K shares, representing a decrease of 6.97%. The firm increased its portfolio allocation in OPK by 14.08% over the last quarter.
Geode Capital Management holds 8,411K shares representing 1.09% ownership of the company. In it's prior filing, the firm reported owning 7,987K shares, representing an increase of 5.03%. The firm increased its portfolio allocation in OPK by 13.81% over the last quarter.
Millennium Management holds 6,422K shares representing 0.83% ownership of the company. In it's prior filing, the firm reported owning 3,720K shares, representing an increase of 42.07%. The firm increased its portfolio allocation in OPK by 108.93% over the last quarter.
Opko Health Background Information
(This description is provided by the company.)
Opko Health Inc. is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies.
Additional reading:
- OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today
- WAIVER UNDER AND AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT
- License and Research Collaboration Agreement by and between ModeX Therapeutics, Inc., OPKO Health, Inc. (with respect to certain sections), and Merck Sharp & Dohme LLC dated March 7, 2023.
- OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today
- OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
